Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome

A double-blind, controlled study

Tsu F. Yeh, Joseph A. Torre, Alok Rastogi, Martin A. Anyebuno, Rosita S. Pildes

Research output: Contribution to journalArticle

186 Citations (Scopus)

Abstract

To determine whether early (≤12 hours) postnatal dexamethasone therapy would facilitate removal of the endotracheal tube and improve outcome in premature infants with severe respiratory distress syndrome, we conducted a double-blind, controlled study of 57 infants whose birth weights were <2000 gm. The placebo (n=29) and treated (n=28) groups were comparable in birth weight (mean ± SD: 1273±323 vs 1318±359 gm), gestational age (30.1±2.1 vs 30.8±2.7 weeks), postnatal age (8.7±3.1 vs 8.5±3.1 hours), and pulmonary function at the start of the study. The dose of dexamethasone was 1.0 mg/kg/day for 3 days and then was progressively decreased for 12 days. Infants in the dexamethasone group had significantly higher pulmonary complicance, tidal volume, and minute ventilation, and required lower mean airway pressure for ventilation than infants in the placebo group. The endotracheal tube was successfully removed from more infants in the dexamethasone group (16/28 vs 8/29; p<0.025). Nineteen infants (65%) in the placebo group and 11 (39%) in the dexamethasone group (p<0.05) had lung injuries. Dexamethasone therapy was associated with a temporary increase in blood pressure and plasma glucose concentration and a delay in somatic growth. We conclude that early postnatal dexamethasone therapy improves pulmonary status, facilitates removal of the endotracheal tube, and minimizes lung injuries in premature infants with severe respiratory distress syndrome.

Original languageEnglish
Pages (from-to)273-282
Number of pages10
JournalThe Journal of Pediatrics
Volume117
Issue number2 PART 1
DOIs
Publication statusPublished - Jan 1 1990
Externally publishedYes

Fingerprint

Double-Blind Method
Premature Infants
Dexamethasone
Placebos
Lung Injury
Birth Weight
Lung
Therapeutics
Ventilation
Tidal Volume
Gestational Age
Blood Pressure
Pressure
Glucose
Growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome : A double-blind, controlled study. / Yeh, Tsu F.; Torre, Joseph A.; Rastogi, Alok; Anyebuno, Martin A.; Pildes, Rosita S.

In: The Journal of Pediatrics, Vol. 117, No. 2 PART 1, 01.01.1990, p. 273-282.

Research output: Contribution to journalArticle

Yeh, Tsu F. ; Torre, Joseph A. ; Rastogi, Alok ; Anyebuno, Martin A. ; Pildes, Rosita S. / Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome : A double-blind, controlled study. In: The Journal of Pediatrics. 1990 ; Vol. 117, No. 2 PART 1. pp. 273-282.
@article{779c97e2f29d4fb1815741c6c5c1b7d0,
title = "Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: A double-blind, controlled study",
abstract = "To determine whether early (≤12 hours) postnatal dexamethasone therapy would facilitate removal of the endotracheal tube and improve outcome in premature infants with severe respiratory distress syndrome, we conducted a double-blind, controlled study of 57 infants whose birth weights were <2000 gm. The placebo (n=29) and treated (n=28) groups were comparable in birth weight (mean ± SD: 1273±323 vs 1318±359 gm), gestational age (30.1±2.1 vs 30.8±2.7 weeks), postnatal age (8.7±3.1 vs 8.5±3.1 hours), and pulmonary function at the start of the study. The dose of dexamethasone was 1.0 mg/kg/day for 3 days and then was progressively decreased for 12 days. Infants in the dexamethasone group had significantly higher pulmonary complicance, tidal volume, and minute ventilation, and required lower mean airway pressure for ventilation than infants in the placebo group. The endotracheal tube was successfully removed from more infants in the dexamethasone group (16/28 vs 8/29; p<0.025). Nineteen infants (65{\%}) in the placebo group and 11 (39{\%}) in the dexamethasone group (p<0.05) had lung injuries. Dexamethasone therapy was associated with a temporary increase in blood pressure and plasma glucose concentration and a delay in somatic growth. We conclude that early postnatal dexamethasone therapy improves pulmonary status, facilitates removal of the endotracheal tube, and minimizes lung injuries in premature infants with severe respiratory distress syndrome.",
author = "Yeh, {Tsu F.} and Torre, {Joseph A.} and Alok Rastogi and Anyebuno, {Martin A.} and Pildes, {Rosita S.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/S0022-3476(05)80547-5",
language = "English",
volume = "117",
pages = "273--282",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2 PART 1",

}

TY - JOUR

T1 - Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome

T2 - A double-blind, controlled study

AU - Yeh, Tsu F.

AU - Torre, Joseph A.

AU - Rastogi, Alok

AU - Anyebuno, Martin A.

AU - Pildes, Rosita S.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - To determine whether early (≤12 hours) postnatal dexamethasone therapy would facilitate removal of the endotracheal tube and improve outcome in premature infants with severe respiratory distress syndrome, we conducted a double-blind, controlled study of 57 infants whose birth weights were <2000 gm. The placebo (n=29) and treated (n=28) groups were comparable in birth weight (mean ± SD: 1273±323 vs 1318±359 gm), gestational age (30.1±2.1 vs 30.8±2.7 weeks), postnatal age (8.7±3.1 vs 8.5±3.1 hours), and pulmonary function at the start of the study. The dose of dexamethasone was 1.0 mg/kg/day for 3 days and then was progressively decreased for 12 days. Infants in the dexamethasone group had significantly higher pulmonary complicance, tidal volume, and minute ventilation, and required lower mean airway pressure for ventilation than infants in the placebo group. The endotracheal tube was successfully removed from more infants in the dexamethasone group (16/28 vs 8/29; p<0.025). Nineteen infants (65%) in the placebo group and 11 (39%) in the dexamethasone group (p<0.05) had lung injuries. Dexamethasone therapy was associated with a temporary increase in blood pressure and plasma glucose concentration and a delay in somatic growth. We conclude that early postnatal dexamethasone therapy improves pulmonary status, facilitates removal of the endotracheal tube, and minimizes lung injuries in premature infants with severe respiratory distress syndrome.

AB - To determine whether early (≤12 hours) postnatal dexamethasone therapy would facilitate removal of the endotracheal tube and improve outcome in premature infants with severe respiratory distress syndrome, we conducted a double-blind, controlled study of 57 infants whose birth weights were <2000 gm. The placebo (n=29) and treated (n=28) groups were comparable in birth weight (mean ± SD: 1273±323 vs 1318±359 gm), gestational age (30.1±2.1 vs 30.8±2.7 weeks), postnatal age (8.7±3.1 vs 8.5±3.1 hours), and pulmonary function at the start of the study. The dose of dexamethasone was 1.0 mg/kg/day for 3 days and then was progressively decreased for 12 days. Infants in the dexamethasone group had significantly higher pulmonary complicance, tidal volume, and minute ventilation, and required lower mean airway pressure for ventilation than infants in the placebo group. The endotracheal tube was successfully removed from more infants in the dexamethasone group (16/28 vs 8/29; p<0.025). Nineteen infants (65%) in the placebo group and 11 (39%) in the dexamethasone group (p<0.05) had lung injuries. Dexamethasone therapy was associated with a temporary increase in blood pressure and plasma glucose concentration and a delay in somatic growth. We conclude that early postnatal dexamethasone therapy improves pulmonary status, facilitates removal of the endotracheal tube, and minimizes lung injuries in premature infants with severe respiratory distress syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0025286128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025286128&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(05)80547-5

DO - 10.1016/S0022-3476(05)80547-5

M3 - Article

VL - 117

SP - 273

EP - 282

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2 PART 1

ER -